LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Smith & Nephew PLC ADR

Закрыт

35.46 0.68

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

35.13

Макс.

35.81

Ключевые показатели

By Trading Economics

Доход

296M

Продажи

3B

P/E

Средняя по отрасли

31.586

121.746

Дивидендная доходность

2.17

Рентабельность продаж

9.895

Сотрудники

17,000

EBITDA

723M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-1.71% downside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

2.17%

2.26%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

15B

Предыдущая цена открытия

34.78

Предыдущая цена закрытия

35.46

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Smith & Nephew PLC ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 февр. 2026 г., 23:57 UTC

Популярные акции

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 февр. 2026 г., 23:35 UTC

Отчет
Главные движущие силы рынка

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 февр. 2026 г., 23:28 UTC

Отчет

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 февр. 2026 г., 21:47 UTC

Отчет

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 февр. 2026 г., 00:00 UTC

Обсуждения рынка

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 февр. 2026 г., 23:38 UTC

Обсуждения рынка

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 февр. 2026 г., 23:33 UTC

Отчет

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 февр. 2026 г., 23:09 UTC

Обсуждения рынка

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 февр. 2026 г., 22:55 UTC

Отчет
Популярные акции

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 февр. 2026 г., 22:46 UTC

Обсуждения рынка

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 февр. 2026 г., 22:23 UTC

Отчет

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 февр. 2026 г., 22:00 UTC

Отчет

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 февр. 2026 г., 22:00 UTC

Отчет

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 февр. 2026 г., 21:57 UTC

Отчет

XP 4Q Rev BRL4.95B >XP

12 февр. 2026 г., 21:52 UTC

Отчет

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

12 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

12 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

12 февр. 2026 г., 21:47 UTC

Отчет

Morningstar 4Q Rev $641M >MORN

12 февр. 2026 г., 21:39 UTC

Отчет

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 февр. 2026 г., 21:38 UTC

Отчет

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Smith & Nephew PLC ADR Прогноз

Целевая цена

By TipRanks

-1.71% падение

Прогноз на 12 месяцев

Средняя 34.46 USD  -1.71%

Максимум 34.91 USD

Минимум 34 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Smith & Nephew PLC ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

2 ratings

0

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

26.64 / 28.37Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat